1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Safety indices reported at time of the procedure and during follow-up
PRET-1PRET-2PRET
PlatinumHydrogelPlatinumHydrogelPlatinumHydrogel
Procedural complications
    Thromboembolic10 (8.0%)6 (4.9%)1 (1.0%)3 (3.0%)11 (5.0%)9 (4.1%)
    Hemorrhagic2 (1.6%)1 (0.8%)1 (1.0%)1 (1.0%)3 (1.4%)2 (0.9%)
    Other4 (3.2%)6 (4.9%)4 (4.1%)3 (3.0%)8 (3.6%)9 (4.1%)
Anti-GP IIb/IIIa used during embolization8 (6.4%)11 (8.9%)7 (7.2%)4 (4.0%)15 (6.8%)15 (6.8%)
Clinical deterioration at end of procedure5 (4.0%)1 (0.8%)2 (2.1%)3 (3.0%)7 (3.2%)4 (1.9%)
Hospitalization
    Days (median) (min) (max)2 (1) (94)1 (0) (70)1 (0) (51)1 (0) (30)1 (0) (94)1 (0) (70)
    Days >5 for unruptured aneurysms9 (7.2%)7 (5.7%)5 (5.2%)5 (5.1%)14 (6.3%)12 (5.4%)
    Days >15 for ruptured aneurysms10 (8.0%)10 (8.1%)1 (1.0%)011 (5.0%)10 (4.5%)
New imaging findings at discharge17 (13.6)11 (8.9%)7 (7.2%)9 (9.1%)24 (10.8%)20 (9.0%)
mRS >2 at discharge17 (13.6%)9 (7.3%)1 (1.0%)5 (5.1%)18 (8.1%)14 (6.3%)
Discharge destination
    Home107 (85.6%)108 (87.8%)95 (97.9%)92 (92.9%)202 (91.0%)200 (90.1%)
    Other than home18 (14.4%)15 (12.2%)2 (2.1%)7 (7.1%)20 (9.0%)22 (9.2%)
mRS >2 at 1 month11 (8.8%)6 (4.9%)3 (3.1%)5 (5.1%)14 (6.3%)11 (5%)
Location at 1 month
    Home117 (93.6%)116 (94.3%)95 (97.9%)95 (96.0%)212 (95.5%)211 (95.0%)
    Other than home8 (6.4%)7 (5.7%)2 (2.1%)4 (4.0%)10 (4.5%)11 (5%)
AE
    No. reported16187102328
    No. (%) serious10 (62%)8 (44.4%)3 (42.9%)6 (60%)13 (56.5%)14 (50%)
AE attribution (No.) (% of total No. reported)
    Related to treatment14 (87.5%)14 (77.8%)7 (100%)10 (100%)21 (91.3%)24 (85.7%)
    Related to aneurysm2 (12.5%)3 (16.7%)002 (8.7%)3 (10.7%)
    Unrelated01 (5.5%)0001 (3.6%)
  • Note:—Anti-GP IIb/IIIa indicates antiglycoprotein IIb/IIIa; AE, adverse events; min, minimum; max, maximum.